# A Crossover Study to Evaluate the Relative Bioavailability of Two Formulations of Deuterated Remdesivir Hydrobromide for Oral Suspension in Healthy Chinese Adults

> **NCT07510529** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Simcere Pharmaceutical Co., Ltd** · enrollment: 48 (estimated)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** T-R (Test-Reference drug)
- **DRUG:** R-T (Reference-Test drug)

## Key facts

- **NCT ID:** NCT07510529
- **Lead sponsor:** Simcere Pharmaceutical Co., Ltd
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-20
- **Primary completion:** 2026-05-31
- **Final completion:** 2026-06-30
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07510529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07510529, "A Crossover Study to Evaluate the Relative Bioavailability of Two Formulations of Deuterated Remdesivir Hydrobromide for Oral Suspension in Healthy Chinese Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07510529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*